Time for a change in breast cancer therapy?

Hosp Med. 2004 Dec;65(12):724-9. doi: 10.12968/hosp.2004.65.12.724.

Abstract

Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / surgery
  • Breast Neoplasms / therapy*
  • Chemotherapy, Adjuvant
  • Female
  • Forecasting
  • Humans
  • Postmenopause
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal